Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01176435 · ClinicalTrials.gov registry record · Phase 2
Trial of L-DOPA as a Treatment to Improve Vision in Albinism
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01176435 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 45 participants.
The verdict
NCT01176435, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pigment production. Increased melanin has previously been shown to be associated with improved vision.
Interventions
- DRUG Placebo
- DRUG Levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01176435
The ClinicalTrials.gov registry entry for NCT01176435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01176435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01176435 about?
NCT01176435 is a clinical study titled "Trial of L-DOPA as a Treatment to Improve Vision in Albinism". This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pi...
What is the current status of trial NCT01176435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2010-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01176435?
The interventions under investigation include: Placebo (DRUG), Levodopa (DRUG).
Who is sponsoring clinical trial NCT01176435?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.